The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. / Rolin, Bidda; Larsen, Marianne O; Gotfredsen, Carsten F; Deacon, Carolyn F; Carr, Richard D; Wilken, Michael; Knudsen, Lotte Bjerre.

In: American Journal of Physiology: Endocrinology and Metabolism, Vol. 283, No. 4, 2002, p. E745-52.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Rolin, B, Larsen, MO, Gotfredsen, CF, Deacon, CF, Carr, RD, Wilken, M & Knudsen, LB 2002, 'The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.', American Journal of Physiology: Endocrinology and Metabolism, vol. 283, no. 4, pp. E745-52. https://doi.org/10.1152/ajpendo.00030.2002

APA

Rolin, B., Larsen, M. O., Gotfredsen, C. F., Deacon, C. F., Carr, R. D., Wilken, M., & Knudsen, L. B. (2002). The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. American Journal of Physiology: Endocrinology and Metabolism, 283(4), E745-52. https://doi.org/10.1152/ajpendo.00030.2002

Vancouver

Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. American Journal of Physiology: Endocrinology and Metabolism. 2002;283(4):E745-52. https://doi.org/10.1152/ajpendo.00030.2002

Author

Rolin, Bidda ; Larsen, Marianne O ; Gotfredsen, Carsten F ; Deacon, Carolyn F ; Carr, Richard D ; Wilken, Michael ; Knudsen, Lotte Bjerre. / The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. In: American Journal of Physiology: Endocrinology and Metabolism. 2002 ; Vol. 283, No. 4. pp. E745-52.

Bibtex

@article{7df1dd90ab4c11ddb5e9000ea68e967b,
title = "The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.",
abstract = "NN2211 is a long-acting, metabolically stable glucagon-like peptide-1 (GLP-1) derivative designed for once daily administration in humans. NN2211 dose dependently reduced the glycemic levels in ob/ob mice, with antihyperglycemic activity still evident 24 h postdose. Apart from an initial reduction in food intake, there were no significant differences between NN2211 and vehicle treatment, and body weight was not affected. Histological examination revealed that beta-cell proliferation and mass were not increased significantly in ob/ob mice with NN2211, although there was a strong tendency for increased proliferation. In db/db mice, exendin-4 and NN2211 decreased blood glucose compared with vehicle, but NN2211 had a longer duration of action. Food intake was lowered only on day 1 with both compounds, and body weight was unaffected. beta-Cell proliferation rate and mass were significantly increased with NN2211, but with exendin-4, only the beta-cell proliferation rate was significantly increased. In conclusion, NN2211 reduced blood glucose after acute and chronic treatment in ob/ob and db/db mice and was associated with increased beta-cell mass and proliferation in db/db mice. NN2211 is currently in phase 2 clinical development.",
author = "Bidda Rolin and Larsen, {Marianne O} and Gotfredsen, {Carsten F} and Deacon, {Carolyn F} and Carr, {Richard D} and Michael Wilken and Knudsen, {Lotte Bjerre}",
note = "Keywords: Animals; Blood Glucose; Body Weight; Cell Division; Diabetes Mellitus, Type 2; Eating; Female; Glucagon; Glucagon-Like Peptide 1; Hyperglycemia; Insulin; Islets of Langerhans; Mice; Mice, Inbred C57BL; Mice, Obese; Peptide Fragments; Peptides; Protein Precursors; Venoms",
year = "2002",
doi = "10.1152/ajpendo.00030.2002",
language = "English",
volume = "283",
pages = "E745--52",
journal = "American Journal of Physiology: Endocrinology and Metabolism",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "4",

}

RIS

TY - JOUR

T1 - The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.

AU - Rolin, Bidda

AU - Larsen, Marianne O

AU - Gotfredsen, Carsten F

AU - Deacon, Carolyn F

AU - Carr, Richard D

AU - Wilken, Michael

AU - Knudsen, Lotte Bjerre

N1 - Keywords: Animals; Blood Glucose; Body Weight; Cell Division; Diabetes Mellitus, Type 2; Eating; Female; Glucagon; Glucagon-Like Peptide 1; Hyperglycemia; Insulin; Islets of Langerhans; Mice; Mice, Inbred C57BL; Mice, Obese; Peptide Fragments; Peptides; Protein Precursors; Venoms

PY - 2002

Y1 - 2002

N2 - NN2211 is a long-acting, metabolically stable glucagon-like peptide-1 (GLP-1) derivative designed for once daily administration in humans. NN2211 dose dependently reduced the glycemic levels in ob/ob mice, with antihyperglycemic activity still evident 24 h postdose. Apart from an initial reduction in food intake, there were no significant differences between NN2211 and vehicle treatment, and body weight was not affected. Histological examination revealed that beta-cell proliferation and mass were not increased significantly in ob/ob mice with NN2211, although there was a strong tendency for increased proliferation. In db/db mice, exendin-4 and NN2211 decreased blood glucose compared with vehicle, but NN2211 had a longer duration of action. Food intake was lowered only on day 1 with both compounds, and body weight was unaffected. beta-Cell proliferation rate and mass were significantly increased with NN2211, but with exendin-4, only the beta-cell proliferation rate was significantly increased. In conclusion, NN2211 reduced blood glucose after acute and chronic treatment in ob/ob and db/db mice and was associated with increased beta-cell mass and proliferation in db/db mice. NN2211 is currently in phase 2 clinical development.

AB - NN2211 is a long-acting, metabolically stable glucagon-like peptide-1 (GLP-1) derivative designed for once daily administration in humans. NN2211 dose dependently reduced the glycemic levels in ob/ob mice, with antihyperglycemic activity still evident 24 h postdose. Apart from an initial reduction in food intake, there were no significant differences between NN2211 and vehicle treatment, and body weight was not affected. Histological examination revealed that beta-cell proliferation and mass were not increased significantly in ob/ob mice with NN2211, although there was a strong tendency for increased proliferation. In db/db mice, exendin-4 and NN2211 decreased blood glucose compared with vehicle, but NN2211 had a longer duration of action. Food intake was lowered only on day 1 with both compounds, and body weight was unaffected. beta-Cell proliferation rate and mass were significantly increased with NN2211, but with exendin-4, only the beta-cell proliferation rate was significantly increased. In conclusion, NN2211 reduced blood glucose after acute and chronic treatment in ob/ob and db/db mice and was associated with increased beta-cell mass and proliferation in db/db mice. NN2211 is currently in phase 2 clinical development.

U2 - 10.1152/ajpendo.00030.2002

DO - 10.1152/ajpendo.00030.2002

M3 - Journal article

C2 - 12217892

VL - 283

SP - E745-52

JO - American Journal of Physiology: Endocrinology and Metabolism

JF - American Journal of Physiology: Endocrinology and Metabolism

SN - 0193-1849

IS - 4

ER -

ID: 8417539